Background Hepatocellular carcinoma (HCC) is a highly lethal cancer and the second leading cause of cancer-related deaths worldwide. As demonstrated in other solid neoplasms and HCC, infiltrating CD8+ T cells seem to be related to a better prognosis, but the mechanisms affecting the immune landscape in HCC are still mostly unknown. Necroptosis is a programmed, caspase-independent cell death that, unlike apoptosis, evokes immune response by releasing damage-associated molecular factors. However, in HCC, the relationship between the necroptotic machinery and the tumor-infiltrating lymphocytes has not been fully investigated so far.
Methods We investigated the association between the main necroptosis-related genes, that is, RIPK1, RIPK3, MLKL-p, and CD3+/CD8+ tumor-infiltrating T cell by RNA-seq data analysis in 371 patients with primary HCC from The Cancer Genome Atlas and then by immunohistochemistry in two independent cohorts of HCC patients from Italy (82) and Japan (86).
Results Our findings highlighted the immunogenetic role of necroptosis and its potential prognostic role in HCC: RIPK1, RIPK3 and MLKL-p were found significantly associated with intratumoral CD3+ and CD8+ T cells. In addition, multivariate survival analysis showed that the expression of RIPK1, RIPK3 and MLKL-p was associated with better overall survival in the two independent cohorts.
Conclusions Our results confirmed the immunogenetic properties of necroptosis (NCP) in human HCC, showing that tumor-infiltrating lymphocytes (TILs) and, specifically, CD8+ T cells accumulate in tumors with higher expression of the necroptosis-related genes. These results suggest the importance of further studies to better assess the specific composition, as well as the functional features of the immune environment associated with a necroptotic signature in order to explore new possible diagnostic and immunotherapeutic scenarios.
- liver neoplasms
- adaptive immunity
Data availability statement
Data are available on reasonable request.
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related human deaths.1 Most HCCs arise in cirrhotic liver, related to chronic viral infections by hepatitis C virus or hepatitis B virus, alcohol abuse, aflatoxin exposure or metabolic or autoimmune liver diseases.2 Since most HCCs are diagnosed in an advanced stage, gold-standard treatments like tumor resection, local radiofrequency ablation and, in selected cases, liver transplantation3 are ineffective, with a high rate of recurrence and low survival.2 Moreover, HCC clinical outcomes can be different in patients with the same tumor, node and metastasis (TNM) stage, and effective prognostic markers are still largely limited so far.
The role of the tumor microenvironment (TME) in promoting tumor aggressiveness has been well established in the last years,4 but little is known about the complex and highly dynamic network driving immune and stromal cell interactions within the tumor. Features such as entity, degree, and spatial distribution of infiltrating T cells can be used to obtain a more accurate stratification of the patients, according to phenotype, prognosis, and treatment susceptibility.5 ,6 The prognostic role of the intratumoral CD3+ and CD8+ T cells has been already described in association with the standard TNM staging system,7 ,8 but TME intrinsic features have been poorly investigated in HCC so far.
Programmed cell death is known to have a great impact in featuring the TME ecosystem.9 Transformed hepatocytes can die by different types of regulated cell death pathways, and the most known are apoptosis and necroptosis (NCP).10 In contrast to apoptosis, which typically limits inflammation, NCP induces membrane destabilization followed by cellular swelling and lysis, with consequent dissemination of intracellular constituents. NCP pathway is activated by the co-presence of inhibited caspase 8 and the receptor-interacting serine/threonine-protein kinase 1 (RIPK1), which promotes NCP through the recruitment and the activation of the receptor-interacting serine/threonine-protein kinase 3 (RIPK3). Activated RIPK3 promotes the activation of the mixed lineage kinase domain-like protein (MLKL), which migrates to the cell membrane and then oligomerizes to form a channel-like structure promoting the membrane destabilization and disruption. Disseminated cellular elements are identified as damage-associated molecular patterns (DAMPs).11 DAMPs floating within the extracellular space are then recognized by immature antigen-presenting cells that may engage adaptive immunity, boosting tumor surveillance through the cytotoxic CD8+ T cells activation.12
In this study, we assessed the impact of NCP in influencing the lymphocyte landscape of HCC. We first evaluated the association between the expression of the genes involved in NCP and the CD8+ infiltration using RNA-seq data of 371 patients with primary HCC from The Cancer Genome Atlas (TCGA). Second, in line with the results obtained from the computational analysis, we evaluated the expression of the main NCP-associated proteins (i.e., RIPK1, RIPK3 and MLKL-p) by immunohistochemistry (IHC) in two independent cohorts of 86 Italian and 82 Japanese HCC patients, suggesting a necroptosis core score (NCS) to quantify the expression of the NCP machinery in the tissue samples. Associations between NCS and the tumor-infiltrating lymphocytes CD3+ and CD8+ were then assessed. Finally, we retrospectively investigated the prognostic impact of NCS and the intratumoral CD3+ and CD8+ T cells infiltrate. To our knowledge, this is the most extensive study exploring the necroptotic machinery in HCC from different cohorts of patients.
Materials and methods
Bioinformatics and statistical analysis of TCGA data
We initially investigated to which extent the NCP pathway is correlated to CD8+ T cell infiltration in public HCC data, following the pipeline described in figure 1A. Three hundred and seventy-one primary solid tumors with available bulk RNA-seq expression data were considered from the TCGA Liver Hepatocellular Carcinoma (LIHC) project.13 Ninety-one primary solid tumors were filtered out to exclude cases with pharmaceutical or radiation treatments before surgery, cases with a history of neoadjuvant treatments or other malignancies and cases with residual tumor. Clinical data of the selected patients are displayed in table 1. From the complex mixture of cells in HCC RNA-seq bulk samples, immune cell infiltration was estimated through a consensus score built from three popular deconvolution algorithms used to estimate the proportion of specific cell populations (CD8+ T cells in our case) from gene expression data (methods details in online supplemental file 1 and figure S1; estimations and final consensus ranking available in online supplemental table 1). Considering the 25th and 75th percentiles of the consensus ranking, 70+70 samples at low and high TILs infiltration were isolated.
Logistic regression was first applied to each gene belonging to the NCP pathway (n=163, annotations from KEGG database14) to test its association with CD8+ T cell infiltration. Then, considering the interaction network of the NCP pathway, multivariate logistic regression was applied to all the groups of genes belonging to a common (shortest) path of interactions in the network including at least one gene previously found significantly associated with CD8+ infiltration. In both analyses, tumor purity was considered as confounder in the models (data from Aran et al 15). Likelihood ratio test was applied to test the significance in each model, considering Benjamini-Hochberg adjusted p-values <0.05 as significant. For the multivariate analysis, p-values <0.05 in the Wald tests of all the estimated coefficients characterizing the contribution of the expression levels of each gene in the path were also required for the statistical significance. Analyses were performed with R (V.4.0.3, https://www.R-project.org/).
Patients and specimens description
Two cohorts of 82 Italian and 86 Japanese patients that underwent surgical resection for primary HCC between 2008 and 2012 were considered (figure 2A and table 2). Representative formalin-fixed and paraffin-embedded (FFPE) HCC specimens for each patient were retrieved from the archives of the Pathology Unit of the University of Padova and of the Department of Diagnostic Pathology of Kurume University Hospital.
The following inclusion criteria were considered: (A) European/Asian ethnicity with available follow-up data; (B) histologically complete resection (R0); (C) known etiology; and (D) availability of biological material.
All cases were reviewed to confirm the histological diagnosis following the WHO classification of tumors.16 All the experimental procedures were performed according to the 1964 Helsinki declaration and its later amendments, following the REporting recommendations for tumor MARKer prognostic studies guidelines.17
IHC and immunofluorescence microscopy (IF)
IHC was performed following the manufacturer’s suggestions on 4 µm sections from the most representative FFPE samples as previously described,18 using primary antibodies against RIPK1, RIPK3 and MLKL-p (antibody specifications are displayed in table S1 in online supplemental file 1). Under the optical microscope, cytoplasmic or membrane immunostaining for RIPK1, RIPK3, and MLKL-p were assessed as percentage of positive cancer cells and then stratified into four groups (figure 2B, from A1 to C4): 0 (expression <5%); 1+ (expression 5%–25%); 2+ (expression 25%–65%); and 3+ (expression >65%). A score for each marker was performed by two pathologists (LN and VM; concordance between observers is shown in figure S2 in online supplemental file 1). Representative immunostaining for each necroptotic marker and its role in the pathway are displayed in figure 3. To evaluate the overall expression of NCP in each case, we calculated a NCS ranging from 0 to 9, defined by the sum of the single scores of each marker. NCS was used to stratify patients in three groups according to the level of activated NCP (low: NCS ranging from 0 to 3; intermediate: NCS ranging from 4 to 6; and high: NCS ranging from 7 to 9). Infiltrating lymphocytes were stained with CD3+ and CD8+ antibodies and then automatically detected in tumorous tissues using a custom-made algorithm created with Visiopharm software, V.184.108.40.206 (Visiopharm, Hoersholm, Denmark),19 as described in online supplemental file 1. Slices from Italian and Japanese cohorts were set up under the same experimental conditions.
IF on FFPE sections of a representative case was performed to confirm colocalization of the necroptotic proteins in tumor cells. The selected sample was labeled by a sequential double stain to analyze the simultaneous expression of the antigens RIPK3-RIPK1 and MLKL-RIPK1, and then examined by Leica DMI6000CS fluorescence microscope (Leica Microsystem, Wetzlar, Germany). Sections were analyzed with differential interference contrast (DIC) and fluorescence objectives. Protocol details are described in online supplemental file 1.
Statistical analysis in Italian and Japanese cohorts
In each cohort, both extratumoral and intratumoral density distributions of CD3+ and CD8+ T cells were compared with different NCS levels through Wilcoxon rank-sum test to assess the association between NCP and the immune infiltration, considering adjusted Benjamini-Hochberg p-values <0.05 as statistically significant. Overall (OS) and disease-free survival (DFS) were estimated by Kaplan-Meier curves and Cox proportional hazard models, considering the two cohorts both separately and joint stratifying by cohort. Age, gender, etiology, alpha-fetoprotein tumor marker, stage, Child-Pugh staging system, Barcelona Clinic Liver Cancer Staging System and multinodularity were considered as confounders in the models, selecting them with a step-down procedure based on a χ2 test for goodness of fit: all the available confounders were first included in the full model considering main effects only, and then sequentially removed if their removal did not result in a significant change of the estimates. The significance of the final model was evaluated in terms of both log-rank and likelihood ratio tests for the significance of the coefficient associated with the variable of interest in the model, used to derive the corresponding hazard ratios (HRs) and confidence intervals (CIs). Both NCS and the single receptors (RIPK1, RIPK3, and MLKL), as well as the distributions of CD3+ and CD8+ T cells densities, were evaluated separately. For T cell densities, discretized values were considered using quantiles and dividing the corresponding extratumoral/intratumoral distributions into three uniformly distributed levels at low, intermediate and high densities to easily compare them with NCS. Analyses were performed with R (V.4.0.3, https://www.R-project.org/).
Genes involved in necroptosis mainly associated with inferred CD8+ T cells infiltration
No statistically significant differences were observed for demographic and pathological data of the 70+70 TCGA-LIHC patients between low and high infiltration of CD8+ T cells (see table S2 and figure S3 in online supplemental file 1); therefore, no other confounding factors were added to the logistic models testing for the associations with the immune infiltration. The univariate logistic regression selected 10 genes from the necroptosis pathway, including both RIPK3 and MLKL, as significantly associated to CD8+ T cell infiltration (figure 1B and red nodes in figure 1C), which showed higher expression in samples at high CD8+ T cell infiltration. Additional genes were then selected through the multivariate analysis that might interact with the process of immune infiltration (blue nodes in figure 1C). As expected, the complex RIPK3/MLKL resulted enhanced at high CD8+ infiltration and the interactions RIPK1-->RIPK3, RIPK3-->MLKL and RIPK1-->RIPK3-->MLKL were found eight times among the 19 paths (red edges in figure 1C) resulted statistically significant from the multivariate analysis (see table S3 in online supplemental file 1). Looking at the other selected genes/paths, the association between the complex RIPK1/RIPK3/MLKL and the immune infiltration seems to be mainly activated by interferons (IFNG, IFNGR1), which are known to regulate innate and acquired immunity, resistance to viral infections, and cell survival/death (figure 1C). Specifically, IFNGR1 activates the JAK-STAT signaling pathway, leading to the transcription of downstream genes including those related with the necrosome formation. In addition, ZBP1, a Z-DNA-binding protein that can be induced by IFNs, was selected and found to increase its expression in samples at high CD8+ T cell infiltration. Like RIPK1 and RIPK3, ZBP1 is a RHIM (RIP homotypic interaction motif) domain-containing protein, implying its potential role in associating with RIPK1 and RIPK3 to participate in necroptosis.20
Despite CASP8 did not show a statistically significant underexpression in samples at high CD8+ T cell infiltration, there is an overexpression of CASP1, which is known to be activated by inflammasomes and promotes both the maturation and the secretion of proinflammatory cytokines. This process is also confirmed by the coactivation of NLRP3 that drives the inflammasome activity and the proinflammatory cytokine ILB1. Finally, interactions between MLKL and the endosomal sorting complex required for transport-III (including CHMP1A, CHMP1B, CHMP3, CHMP4A and CHMP4C), which plays a key role in repairing the damaged plasma membranes, were selected.
Clinicopathological data are resumed in table 2. Comparing the two cohorts, Japanese cohort showed more cases with advanced tumor stage, that is, 43% (37 patients) with stage III or IV, and portal thrombosis (63%, 54 patients) than Italian cohort, that is, 21% (17 patients) with stage III or IV, and 6.1% (5 cases) with portal thrombosis.
IHC and fluorescence imaging
Scores of each marker are listed in table S4 in online supplemental file 1. In the Japanese cohort, NCP markers combined as NCS resulted to low, intermediate and high in 23%, 49% and 28% of the patients, while 27%, 54% and 20% of the patients in the Italian cohort, respectively. No significant differences were observed between the cohorts in terms of NCS. Considering each marker separately, Japanese patients showed more RIPK1 positive (ie, score >0) immunostaining (p=0.0017), while no significant differences were observed for both RIPK3 and MLKL-p.
TILs showed a mean density of 612.93 cells/mm2 while infiltrating CD8+ T cells showed a mean density of 337.45 cells/mm2. TILs and intratumor CD8+ T cells were correlated (Pearson’s correlation 0.784; p value <0.001), and no significant differences were observed between the cohorts (table 2).
Considering multiplex fluorescent microscopy, RIPK1, RIPK3, and MLKL-p resulted strongly colocalized in the same tumor cells (example shown in figure 4; Pearson’s correlation: 0.86–0.98 for MLKL vs RIPK1 and 0.89–0.98 for RIPK3 vs RIPK1). Morphology of necroptotic cells showed an enlargement (DIC imaging) and disappearance of the nuclei (DAPI signal) in tumor cells colocalizing RIPK1, RIPK3, and MLKL-p.
Association of NCS with CD3+ and CD8+ T cells infiltration
Increased levels of NCS showed statistically significant association with higher CD3+ and CD8+ T cells intratumoral, but not extratumoral, infiltration in both cohorts (figure 5A). Considering the three receptors independently, this association was not always found preserved for all the receptors and the cohorts (figure S4A in online supplemental file 1). However, considering the densities of CD3+ and CD8+ dichotomized by their median value, CD8+ was found significantly associated with all the receptors in both cohorts, while CD3+ showed significant associations with MLKL and RIPK1 in the Italian cohort and with MLKL and RIPK3 in the Japanese cohort (figure S4B in online supplemental file 1).
Prognostic relevance of NCS in hepatocarcinoma
Considering survival and relapse at 5 years of follow-up, we found significant differences between Italian and Japanese cohorts in terms of OS and, partially, DFS (table 2 and figure S5 in online supplemental file 1, with Kaplan-Meier p values 1e-04 in OS and 0.054 in DFS). Therefore, the prognostic relevance of NCS in OS and DFS was assessed both in the two cohorts separately and in the joint dataset stratifying by cohort. NCS was found significantly correlated with OS both when the cohorts were considered separately (figure 5B) and when they were joined (figure S6 in online supplemental file 1), while for DFS the significance was observed only in the Italian cohort and in the joint dataset (results from Cox models in table 3 and table S5 in online supplemental file 1). Considering the three receptors separately, RIPK3 showed significant association with OS both when the cohorts were considered separately and when they were joined, while both RIPK1 and MLKL showed significant association in the Italian, but not Japanese, cohort and in the joint dataset (table S6 in online supplemental file 1). In terms of DFS, only RIPK1 was significantly associated in the Italian, but not Japanese, cohort and when the cohorts were joined. Focusing on the immune infiltration, only intratumoral CD8+ T cell infiltration showed significant association with OS in the Italian cohort and in the joint dataset (figure S7 in online supplemental file 1), with results in the Japanese cohort extremely close to the significance threshold (log-rank test p value=0.0205 and likelihood ratio test p value=0.0517, table S7 in online supplemental file 1).
Finally, we checked on the clinical data from TCGA-LIHC whether the results observed for OS in our cohorts are also confirmed at mRNA level by defining a combined score of the three receptors from RNA-seq data, as done for NCS. Specifically, we discretized the gene expression of each receptor into four levels, considering the quantiles with thresholds equal to those used to quantify the expression of RIPK1, RIPK3 and MLKL in our cohorts, that is, 0 (<5%); 1+ (5%–25%); 2+ (25%–65%); and 3+ (>65%), and then assembled them into a score named as NCSrna in the following. Since no statistically significant differences in terms of ethnicity of the patients were observed (p value 0.23, figure S8 in online supplemental file 1), the whole dataset (279 samples with available information for OS) was analyzed to evaluate the prognostic relevance of NCSrna. For the Cox models, clinical factors reported in table 1 were considered as potential confounders, excluding those reporting >5% of the samples with missing values and selecting them according to the same step-down procedure described in Materials and methods for our cohorts. Survival analysis was applied to NCSrna, to the three receptors separately and to the CD8+ T cell infiltration. For this latter, we kept the previous classification of 140 patients at low and high immune infiltration classifying the other patients at an intermediate infiltration level. Results confirmed the significant associations found among NCP, CD8+ T cell infiltration, and OS (figure S9 and table S8 in online supplemental file 1). Considering the three receptors independently, only RIPK3 was statistically significant for prognosis alone (table S8 in online supplemental file 1).
The links between the cancer features and the immune TME is to date a well-accepted paradigm; however, the factors driving TME composition and functions, as well as TILs recruitments are still largely unknown.21 Within this context, NCP could play a role as a possible immune regulator.22 Immunogenicity of NCP in tissues has been extensively demonstrated; however, its immunological and clinical impact in cancer is still poorly investigated. So far, both in vitro and in vivo experimental studies showed that dendritic cells and other antigen presenting cells (APCs) may be activated by the DAMPs released by the necroptotic tumor cells that, in turn, boost a specific antitumoral immune response through cross-priming of cytotoxic CD8+ T cells.23 24 ,25 This model may explain, at least in part, the hypothesis that NCP suppression in cancer cells should reduce the number of tumor-derived epitopes released and identifiable by APC, suggesting NCP downregulation as a possible immune escape strategy. This observation is consistent with studies showing a correlation between the downregulation of RIPK1, RIPK3, or MLKL with poor prognosis in several cancers.26 However, not all of them necessarily show NCP downregulation: correlation between upregulated NCP factors and worse prognosis has been previously found in glioblastoma and lung cancer.26 The ambiguous role played by NCP in cancer biology was also highlighted by another study that showed how NCP occurring in tumor-associated vessels should be implicated in favoring metastatic spreading.27
In this study, for the first time, 371 cases of patients with HCC from TCGA repository were used to perform a comprehensive analysis on 163 genes involved in the necroptotic pathway using annotations from KEGG database.14 In silico analysis revealed that the high expression of the complex RIPK3/MLKL and its combination with RIPK1 was associated with an increased level of CD8+ T cells signature in HCC (figure 1). Therefore, we used two additional cohorts involving 168 HCC patients recruited in Italy (82) and Japan (86) to test our preliminary observation, extending the analysis to a more general T-lymphocyte population CD3-positive. In both cohorts, an increasing level of immunoreaction score of RIPK1, RIPK3 and MLKL-p resulted in an increasing level of intratumoral density of CD3+ and CD8+ T-lymphocytes (figure 5A and figure S4 in online supplemental file 1), enforcing the immunogenic role of NCP in cancer,28 as also previously shown in breast cancer29 and, recently, in cholangiocarcinoma.30
NCS, as well as tumor-infiltrating CD8+ T cells, showed also prognostic relevance in terms of OS, while TILs were not found associated with a worse prognosis in both Italian and Japanese cohorts (figure 5B with table 3 and figure S6 with table S5 in online supplemental file 1 for NCS; figure S7 with table S7 in online supplemental file 1 for CD8+ T cells and TILs). These results were also confirmed in TCGA-LIHC data considering NCS as a combined mRNA expression score of the three receptors and the inferred CD8+ T cells infiltration from RNA-seq data through deconvolution approaches (figure S9 and table S8 in online supplemental file 1). Despite infiltrating CD8+ T cells have been reported as good prognostic markers in HCC,31 a different impact on the prognosis has been observed according to specific cell types, enforcing the evidence that the dynamic evolution in terms of cell composition may show opposite effects on tumor biology, promoting or blocking tumor evolution.32 ,33 Several aspects could explain these differences: (1) our analysis did not take into account the spatial distribution of T cell infiltrates: location of immune infiltrates inside the tumor core and the invasive front have been described as independent predictors of clinical outcome,34 ,35; (2) it is possible that in our cohorts TILs should be principally composed by subsets of T cells including Treg and Th-17 cells linked to immune suppression and cancer progression in several cancers including HCC33 36; (3) immune escape mechanisms and T cell exhaustion phenomena may predominate blocking TILs-mediated tumor suppression37; (4) the lack of an accepted consensus to normalize TILs scoring in HCC across different institutions and also different aetiologies might play a role to explain these differences.
In our cohorts, all the three receptors used to define NCS were found significantly associated with OS in the stratified Cox model, while when the two cohorts were analyzed separately, only RIPK3 was able to preserve a significant association with OS in both Italian and Japanese cohorts, while RIPK1 and MLKL-p were found significantly correlated with worse prognosis only in the Italian cohort (table S6 in online supplemental file 1). These differences might also be due to the limited number of patients available by considering each cohort separately. However, the prognostic effect of NCS observed in our study highlights its real utility within clinical management and the need to be further investigated in future studies on larger cohorts. NCS assessment could be further improved by automatic assessment through image analysis tools, which may provide a more objective and standardizable results. In support of these observations, the higher prognostic relevance of RIPK3 in HCC with respect to the other two receptors was also confirmed at RNA level in the TCGA-LIHC cohort (table S8 in online supplemental file 1). Although hepatocytes clearly express MLKL at basal conditions, which in this study showed the strongest association with CD8+ and TILs infiltration (figure S4 in online supplemental file 1), the presence of RIPK3 in liver cells has been controversial, and it might only be induced in certain disease conditions of the liver.38 Recently, Afonso and colleagues39 showed that hepatic RIPK3 correlates with NAFLD severity in humans and mice, playing a key role in managing liver metabolism, damage, inflammation, fibrosis and carcinogenesis. However, results found in RIPK1 showed some differences with respect to RIPK3 and MLKL. In our survival analysis, RIPK1 was the only receptor showing some prognostic relevance also in terms of DFS, while in silico analysis showed that RIPK1 did not result significantly active alone with respect to the immune infiltration, but in combination with other genes (mainly STATs and RIPK3). In addition, both CYLD, the RIPK1-deubiquitinating enzyme cylindromatosis required for optimal necroptotic responses, and TNFAIP3, promoting RIPK1 ubiquitination suppressing necroptosis by deubiquitinating RIPK3,40 were selected as significantly associated with immune infiltration in HCC (figure 1). However, TNFAIP3 was selected only when combined with other genes (table S3 in online supplemental file 1). RIPK1 is recognized as a protein with ‘two faces’: one promoting cell survival through its scaffolding properties and one favoring cell death through its kinase activity,41 ,42 Van et al 43 showed that RIPK1 can either prevent or, combined with NF-κB, drive hepatocyte apoptosis, chronic liver disease, and cancer according to the presence or absence of the NF-κB essential modulator. Therefore, considering the crosstalk of RIPK1 in apoptosis, necroptosis, and NF-κB pathways, the inhibition of RIPK3 kinase activity seems to be a more specific therapeutic target for necroptosis in HCC. Finally, our in silico analysis highlighted other potential genes and interactions that might enhance the immune response in HCC and which can be considered for future validations (figure 1 and table S3 in online supplemental file 1). For example, in support of our findings, interferons (IFNs) were recently found to induce necroptosis in RelA-deficient cells, suggesting that NF-κB blocks IFN-induced necroptosis in wild-type cells,44 while Baik et al 45 found that ZBP1 expression is dramatically elevated in necrotic breast tumors, and it mediates necroptosis during the tumor development by inducing the activation of MLKL.
In conclusion, our results confirmed the immunogenetic properties of NCP in human HCC, showing that TILs and CD8+ T cells accumulate in tumors with higher expression of NCP genes. These results suggest the importance of further studies to better assess the composition, the functional and evolutionary features, as well as possible checkpoints targeting the immune environment associated with a necroptotic signature in order to explore new diagnostic and therapeutic scenarios.
Data availability statement
Data are available on reasonable request.
Patient consent for publication
TS received funding specifically appointed to Department of Medical Sciences of University of Torino from the Italian Ministry for Education, University and Research (Ministero dell’Istruzione, dell’Università e della Ricerca—MIUR) under the programme 'Dipartimenti di Eccellenza 2018–2022' Project code D15D18000410001; GC and DS were supported by PRIN2017 (20178S4EK9), Progetti di Rilevante Interesse Nazionale, MIUR. We would like to thank VG for the technical support.
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
LN and TS contributed equally.
Contributors Conceptualization: LN and TS. Experimental design: LN, RC, VM, JA, AK and YN. Bioinformatics: TS. Immunofluorescence: CMR and PS. Data analysis: LN, TS, RC and VM. Statistical analysis: TS, DS and GC. Writing: LN and TS. Supervision: MG, AF, GZ and HY. Guarantor: AF.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.